IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed.
OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease.
METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years.
RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals.
CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
PloS one - 17(2022), 6 vom: 12., Seite e0270607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petržalka, Marko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 29.06.2022 Date Revised 19.07.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0270607 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342804707 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342804707 | ||
| 003 | DE-627 | ||
| 005 | 20231226014949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0270607 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342804707 | ||
| 035 | |a (NLM)35759479 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petržalka, Marko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2022 | ||
| 500 | |a Date Revised 19.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed | ||
| 520 | |a OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease | ||
| 520 | |a METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years | ||
| 520 | |a RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals | ||
| 520 | |a CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a IL2 protein, human |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a CHI3L2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.2.1.14 |2 NLM | |
| 650 | 7 | |a Chitinases |2 NLM | |
| 650 | 7 | |a EC 3.2.1.14 |2 NLM | |
| 700 | 1 | |a Meluzínová, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Libertínová, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Mojžišová, Hana |e verfasserin |4 aut | |
| 700 | 1 | |a Hanzalová, Jitka |e verfasserin |4 aut | |
| 700 | 1 | |a Ročková, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Elišák, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kmetonyová, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Šanda, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Sobek, Ondřej |e verfasserin |4 aut | |
| 700 | 1 | |a Marusič, Petr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 17(2022), 6 vom: 12., Seite e0270607 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:6 |g day:12 |g pages:e0270607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0270607 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 6 |b 12 |h e0270607 | ||